Malignant Mesothelioma: Dual Checkpoint Immunotherapy as New Standard

CheckMate-743 Phase III Trial Approval

• July 17, 2021
• Reading time: 1 minute

On May 27, 2021, Ono Pharmaceutical and Bristol-Myers Squibb jointly announced regulatory approval of combined nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) immune checkpoint blockade for unresectable and recurrent malignant mesothelioma.

Regulatory Basis

Approval was based on interim analysis from CheckMate-743, an international Phase III randomized trial enrolling treatment-naive patients with unresectable malignant pleural mesothelioma.

Trial Design

Treatment Comparison:

• Nivolumab plus ipilimumab (dual checkpoint inhibition)
• Versus placebo plus platinum-based chemotherapy

Primary Endpoint: Overall survival

Key Clinical Outcomes

CheckMate-743 demonstrated that dual immune checkpoint blockade (nivolumab plus ipilimumab) achieves superior overall survival compared to standard platinum chemotherapy in unresectable malignant mesothelioma.

Safety Profile

• Adverse event profile consistent with established immunotherapy safety data
• No novel or unexpected toxicities identified

Clinical Significance

This approval represents a major advance in mesothelioma treatment, establishing dual checkpoint inhibition as a new standard first-line option for patients with unresectable disease, offering survival benefit over conventional chemotherapy.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1